Drug discovery at SCYNEXIS
The complex process of transforming a hit into a clinical candidate requires a broad range of technical skills and capabilities. SCYNEXIS Discovery Research incorporates Medicinal Chemistry, Analytical Chemistry, DMPK and Bioanalytical Chemistry into fully-integrated SCYNEXIS Research Teams to meet specific project demands for our global client base.
SCYNEXIS Discovery Research accelerates drug discovery projects by:
- Discovering pre-clinical candidates (PCC) to treat important diseases
- Providing consultancy on disease target selection and optimization strategy
- Incorporating networks of experts and technologies to drive successful drug discovery projects
- Offering risk-sharing business models to allow cost-containment
SCYNEXIS’ Fully-Integrated Research Teams
Our Research Team leaders are industry-recognized scientists with proven track records in major pharmaceutical and biotech companies including GSK, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly, Dupont and Pfizer. Projects are staffed with seasoned professionals, with more than half holding Ph.D. degrees and averaging more than 15 years of industrial experience. Effective project management and client communication are hallmarks of the SCYNEXIS approach, applied to collaborations on both the local level and on a global scale.
Success with SCYNEXIS
SCYNEXIS has the size and experience to handle projects of any complexity and has been involved in the selection of multiple preclinical and clinical candidates across a variety of therapeutic areas, targets, and technologies including:
As of 2012, we have delivered 11 preclinical and 6 clinical candidates to clients and partners. Our fully-integrated approach including Discovery Biology, DMPK, Bioanalytical, Process Chemistry and cGMP API Manufacturing seamlessly transitions your compounds from hit seeking, hit-to-lead and lead optimization through to candidate selection, process scale-up and clinical material manufacturing: From Concept To Clinic With Speed and Innovation™.
Selected SCYNEXIS contributions in the literature
- Structural, Kinetic, and Pharmacodynamic Mechanisms of D-Amino Acid Oxidase Inhibition by Small Molecules, Journal of Medicinal Chemistry (2013), 56(9), 3710-3724.
- A topical aqueous calcineurin inhibitor for the treatment of naturally occurring keratoconjunctivitis sicca in dogs, Veterinary Ophthalmology (2013), 16(3), 192-197
- Orally active drug candidates from complex natural product leads, Abstracts of Papers, 241st ACS National Meeting & Exposition, Anaheim, CA, United States, March 27-31, 2011 (2011), MEDI-195
- Antifungal agents, PCT Int. Appl. (2009), WO 2009045311 A1 20090409
- Preparation of isoquinolines as modulators of G-protein receptor kinases, PCT Int. Appl. (2007), WO 2007008926 A1 20070118
- Small molecule inhibitors of G-Protein Coupled Receptor Kinase-2 (GRK-2), Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, United States, March 26-30, 2006 (2006), MEDI-120
- Preparation of aryl-fused triazole and pyrazole derivatives and their use as antiparasitic agents against endo- and ectoparasites, PCT Int. Appl. (2008), WO 2008144275 A1 20081127
- Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase, Bioorganic & Medicinal Chemistry Letters (2012), 22(22), 6811-6816
- SAR of 2-amino and 2,4-diamino pyrimidines with in vivo efficacy against Trypanosoma brucei, Bioorganic & Medicinal Chemistry Letters (2011), 21(10), 2816-2819
- Synthesis and biological activity of imidazopyridine anticoccidial agents: Part I, European Journal of Medicinal Chemistry (2007), 42(11-12), 1334-1357